The University of Chicago Header Logo

Connection

Anjana Pillai to Liver Neoplasms

Back to Details
This is a "connection" page, showing publications Anjana Pillai has written about Liver Neoplasms.
Anjana Pillai
Connection Strength
12.304
Liver Neoplasms
  1. The Changing Demographics and Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis. 2025 Feb; 29(1):1-15.
    View in: PubMed
    Score: 0.595
  2. Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
    View in: PubMed
    Score: 0.591
  3. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
    View in: PubMed
    Score: 0.578
  4. ACG Clinical Guideline: Focal Liver Lesions. Am J Gastroenterol. 2024 07 01; 119(7):1235-1271.
    View in: PubMed
    Score: 0.564
  5. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.552
  6. Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy. Surg Oncol Clin N Am. 2024 01; 33(1):159-172.
    View in: PubMed
    Score: 0.546
  7. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int. 2023 02; 22(1):4-6.
    View in: PubMed
    Score: 0.513
  8. HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV. Dig Dis Sci. 2022 08; 67(8):3483-3484.
    View in: PubMed
    Score: 0.496
  9. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther. 2022 02; 55(4):479-480.
    View in: PubMed
    Score: 0.492
  10. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol. 2021 10; 19(10):2020-2024.
    View in: PubMed
    Score: 0.470
  11. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol. 2020 12; 115(12):1960-1969.
    View in: PubMed
    Score: 0.454
  12. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis. 2020 11; 24(4):681-700.
    View in: PubMed
    Score: 0.451
  13. Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 11; 115(11):1733-1736.
    View in: PubMed
    Score: 0.451
  14. Positron Emission Tomography With Computed Tomography as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma: Ready for Prime Time? Liver Transpl. 2020 06; 26(6):746-747.
    View in: PubMed
    Score: 0.436
  15. Approach to Evaluation of Multiple Liver Lesions-Reply. JAMA. 2019 05 28; 321(20):2031-2032.
    View in: PubMed
    Score: 0.408
  16. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 04; 64(4):985-992.
    View in: PubMed
    Score: 0.404
  17. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019 Mar; 13(2):125-137.
    View in: PubMed
    Score: 0.397
  18. Mixed Hepatocellular-Cholangiocarcinoma: Is It Time to Rethink Consideration for Liver Transplantation? Liver Transpl. 2018 10; 24(10):1329-1330.
    View in: PubMed
    Score: 0.390
  19. Influence of Acuity Circles on Hepatocellular Carcinoma and the Interaction of Gender and Race in Liver Transplantation. Clin Transplant. 2024 Dec; 38(12):e70045.
    View in: PubMed
    Score: 0.150
  20. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
    View in: PubMed
    Score: 0.147
  21. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):281-290.e4.
    View in: PubMed
    Score: 0.146
  22. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology. 2025 Mar 01; 81(3):837-852.
    View in: PubMed
    Score: 0.146
  23. Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
    View in: PubMed
    Score: 0.142
  24. Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: A systematic review and meta-analysis. Liver Transpl. 2024 Jun 01; 30(6):595-606.
    View in: PubMed
    Score: 0.142
  25. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
    View in: PubMed
    Score: 0.141
  26. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2024 Mar; 80(3):431-442.
    View in: PubMed
    Score: 0.139
  27. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.
    View in: PubMed
    Score: 0.138
  28. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.
    View in: PubMed
    Score: 0.136
  29. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
    View in: PubMed
    Score: 0.132
  30. Combined heart-liver transplantation practices survey in North America: Evaluation and organ listing practices. Liver Transpl. 2023 06 01; 29(6):591-597.
    View in: PubMed
    Score: 0.132
  31. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023 03; 43(3):695-707.
    View in: PubMed
    Score: 0.131
  32. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.128
  33. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.
    View in: PubMed
    Score: 0.127
  34. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.126
  35. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
    View in: PubMed
    Score: 0.125
  36. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
    View in: PubMed
    Score: 0.120
  37. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol. 2022 01; 20(1):204-215.e6.
    View in: PubMed
    Score: 0.115
  38. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.
    View in: PubMed
    Score: 0.114
  39. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193.
    View in: PubMed
    Score: 0.112
  40. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 02; 20(2):333-347.
    View in: PubMed
    Score: 0.106
  41. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
    View in: PubMed
    Score: 0.103
  42. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
    View in: PubMed
    Score: 0.103
  43. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
    View in: PubMed
    Score: 0.100
  44. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304.
    View in: PubMed
    Score: 0.083
  45. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
    View in: PubMed
    Score: 0.081
  46. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015 Jul; 30(7):1167-74.
    View in: PubMed
    Score: 0.078
  47. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr; 11(4):e1001624.
    View in: PubMed
    Score: 0.071
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.